Search Results
Your search for ,aLl matches 18306 pages
Showing 3651 - 3700Medical Costs and Clinical Value: Playing the Long Game
Even as soaring medical costs strain public and private budgets around the world, patients yearn for therapeutic breakthroughs. Game-changing cancer treatments, emerging antiviral agents, and mRNA vaccines are powerful reminders of medical technology’s potential. But insurance premiums and...
Changing the Natural History of ER-Positive, HER2-Negative Breast Cancer With the Introduction of CDK4/6 Inhibition
It has been 14 years since a collaboration between the University of California, Los Angeles (UCLA) and Pfizer identified a unique role for cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in estrogen receptor (ER)-positive human cell line models and demonstrated that these agents act...
Hematology Highlights From ASCO 2022
A multitude of presentations were available to attendees at the 2022 ASCO Annual Meeting, including hundreds in the hematologic malignancies tracks. In addition to coverage in The ASCO Post of the major news stories at the meeting, here we offer summaries of additional studies of special interest...
Study Reports Time-Limited Venetoclax-Based Regimens of Benefit in Front-Line Treatment of CLL
Time-limited venetoclax-based regimens provide deeper and more durable remissions than chemoimmunotherapy combinations in patients with previously untreated chronic lymphocytic leukemia (CLL), regardless of patients’ fitness, according to late-breaking data presented during the European Hematology...
Survey Finds More Than 80% of Patients With Cancer and Survivors Say Copay Assistance Programs Help Them Afford Their Prescription Drugs
A new Survivor Views survey from the American Cancer Society Cancer Action Network (ACS CAN) showed that a majority of respondents (83%) who had applied to a copay assistance program and were accepted said the assistance enables them to get the medication they otherwise couldn’t afford. However,...
Adjuvant Everolimus Narrowly Misses Statistical Significance in RCC, Except for Very High–Risk Patients
In the phase III EVEREST trial, adjuvant everolimus improved median recurrence-free survival in patients with resected renal cell carcinoma (RCC), but this finding failed to be statistically significant in the total study population of 1,499 patients, according to a prespecified boundary. However,...
COG Trial of Intensive Multimodality Therapy for Extraocular Retinoblastoma
As reported in the Journal of Clinical Oncology by Dunkel et al, the Children’s Oncology Group (COG) ARET0321 trial has shown high 1-year event-free survival rates with intensive multimodality therapy in patients with stage II, III, and IVa extraocular retinoblastoma. Study Details In the...
Children With In Utero Exposure to Maternal Cancer: Short- and Long-Term Outcomes
In a Danish nationwide cohort study reported in the Journal of Clinical Oncology, Greiber et al found no apparent increased risk of mortality, overall somatic disease, or overall psychiatric disease among children exposed in utero to maternal cancer compared with to children without such exposure....
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Two Early-Career Cancer Researchers From Africa Aim to Make a Difference and Never Give Up
In countries with a high income, research in oncology is sponsored by funding agencies and industry, which has meaningfully improved survival outcomes of patients with cancer. In contrast, the African continent is disadvantaged in all aspects of human development, particularly in the fields of...
Use of Menopausal Hormone Therapy and Breast Cancer Mortality
Although aromatase inhibitors are effective in reducing estrogen levels and the risk of cancer recurrence in women diagnosed with hormone receptor–positive breast cancer, they can also cause myriad side effects, including genitourinary problems associated with menopause such as vaginal dryness,...
Living With Hereditary Cancer, Oncologist Mark A. Lewis, MD, Shares His Experiences on Social Media to Assist Others
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, FACP, spoke with Mark A. Lewis, MD, Director of Gastrointestinal Oncology at Intermountain Healthcare, Murray, Utah, and Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a social media...
Eprenetapopt/Azacitidine Maintenance After Allogeneic HSCT for TP53-Mutant AML and MDS
In a phase II trial reported in the Journal of Clinical Oncology, Mishra et al found that maintenance treatment with the first-in-class small-molecule p53 reactivator eprenetapopt plus azacitidine following allogeneic hematopoietic stem cell transplantation (HSCT) was associated with “encouraging”...
Addition of Trabectedin to Doxorubicin in the First-Line Treatment of Advanced Leiomyosarcoma
In the French phase III LMS-04 trial reported in The Lancet Oncology, Pautier et al found that the addition of trabectedin to doxorubicin significantly prolonged progression-free survival as first-line treatment for patients with unresectable or metastatic leiomyosarcoma. Study Details In the...
Caregivers for Patients With Multiple Myeloma Face Mental Health Challenges
Caregivers for patients with multiple myeloma may suffer from higher rates of anxiety and depression than patients themselves, according to a new study published by O’Donnell in Blood Advances. Although medical professionals have long acknowledged the toll a serious or terminal diagnosis can have...
Affirming Health Equity: A Model for Integrative Health Care
Guest Editor’s Note: Despite the increasing use of complementary modalities that include mind-body therapies and natural products, significant disparities exist in integrative health care. Contributing factors include access to care and affordability. In this installment of The ASCO Post’s...
Study Examines Quality-of-Life Outcomes Among Patients Participating in Phase III Randomized Trials of Cancer Drugs
In an analysis that evaluated the outcomes of anticancer drug studies in the advanced disease setting with regard to patient quality of life (QOL), improved QOL outcomes were associated with improved overall survival but not with improved progression-free survival. Almost half of the studies that...
Second-Line Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma Not Intended for HSCT
As reported in The Lancet Oncology by Sehgal et al, the phase II PILOT trial showed that the autologous, CD19-directed chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel produced a high response rate in the second-line treatment of patients with relapsed or refractory large...
New Antibody Therapy Shows Activity in Patients With Medulloblastoma
Effective and safe treatments are needed for medulloblastoma—the most common type of cancerous brain tumor in children—especially for patients whose cancer has spread to the spinal cord. A recent phase I clinical trial has generated promising results for a new blocking antibody therapy that targets ...
New Report Underscores Importance of Health Insurance Status and Cancer Stage at Diagnosis in Relation to Patient Survival
A new report published by Jingxuan Zhao, MPH, and colleagues in CA: A Cancer Journal for Clinicians showed that individuals without health insurance coverage were significantly more likely to be diagnosed with late-stage cancer and have worse survival rates after cancer diagnosis compared to...
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted
On July 13, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Novavax COVID-19 vaccine, adjuvanted, for the prevention of COVID-19 caused by SARS–CoV-2 in individuals aged 18 years and older. “Authorizing an additional COVID-19 vaccine expands the...
Study Reveals Cancer Screening Decreased Worldwide During Height of COVID-19 Pandemic
A study that surveyed cancer screening data included in medical journals worldwide from January 2020 into December 2021 showed significant decreases in the number of screenings for breast, colorectal, and cervical cancers during the early phase of the COVID-19 pandemic. The findings of the study,...
President Biden Appoints Cancer Panel Members, and Cancer Cabinet Unveils Priority Actions
On July 13, President Joe Biden announced his intent to appoint Mitchel Berger, MD; Carol Brown, MD; and Elizabeth M. Jaffee, MD, to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President to advise him...
Responses to Teclistamab Reported in Early-Phase Trial of Highly Refractory Multiple Myeloma
In patients with multiple myeloma exposed or refractory to three standard therapies, treatment with the bispecific antibody teclistamab produced strong and durable responses in the phase I/II MajesTEC-1 study.1 The results of weekly subcutaneous dosing of teclistamab in 165 patients were presented...
Geriatrics Experts Explore Relationship Between Heart Disease and Cancer
Experts’ discussions and recommendations addressing the interface between cancer and heart disease were published by Supriya Mohile, MD, MS, and colleagues in the Journal of the American Geriatrics Society, summarizing sessions from a virtual bench-to-bedside conference hosted by the American...
Poziotinib Shows Activity in EGFR Exon 20–Mutant NSCLC, With Efficacy Dependent on Insertion Location
A phase II clinical trial of poziotinib for patients with non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 mutations found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may ...
Antibody Response to SARS–CoV-2 Wild-Type Virus and Variants After mRNA Vaccination in Patients With NSCLC
In a single-institution study reported in the Journal of Clinical Oncology, Valanparambil et al found that one-quarter of patients with non–small cell lung cancer (NSCLC) had poor antibody responses to the SARS–CoV-2 wild-type (WT) strain after mRNA vaccination, and that neutralizing antibody...
Initial Risk Factors and ‘Time to Cure’ in Childhood and Young Adult Acute Lymphoblastic Leukemia
In an analysis of long-term follow-up of the UKALL2003 trial reported in the Journal of Clinical Oncology, Anthony V. Moorman, PhD, and colleagues found that whereas initial risk of relapse in children and young adults with acute lymphoblastic leukemia differed according to risk factors, risk...
Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma
As reported in The Lancet Oncology by Robin Kate Kelley, MD, and colleagues, the phase III COSMIC-312 trial has shown improved progression-free survival with cabozantinib plus atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma; interim analysis of overall survival showed...
CLN-081 Shows Selective Activity in NSCLC With EGFR Exon 20 Insertions
CLN-081, a novel agent targeted to non–small cell lung cancer (NSCLC) cells harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations—ie, the addition of nucleotide base pairs in exon 20 of the EGFR gene, a known oncogenic driver event—holds promise, according to the results of...
Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
In a phase II study reported in The Lancet Oncology, L. Elizabeth Budde, MD, PhD, and colleagues found that mosunetuzumab—a CD20 × CD3 T-cell–engaging bispecific antibody that redirects T cells to eliminate malignant B cells—produced a high rate of complete response in patients with relapsed or...
Former NCI Director Takes Stock of His Accomplishments and Looks Ahead to the Next Challenge
After nearly 5 years as Director of the National Cancer Institute (NCI), interrupted by 7 months as Acting Commissioner for the U.S. Food and Drug Administration (FDA), Norman E. “Ned” Sharpless, MD, left his position on April 29 to concentrate on his family and contemplate his next career choice....
ASCO’s CancerLinQ and HealthVerity Collaborate to Accelerate Cancer Research
On June 8, 2022, CancerLinQLLC, a wholly owned nonprofit subsidiary of ASCO, and HealthVerity, Inc., announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies. The collaboration...
ASCO Guideline Update for Systemic Melanoma Therapy Addresses New Treatment Option for Uveal Melanoma
A rapid update to the ASCO guideline on systemic therapy for melanoma adds a new recommendation for the treatment of patients with metastatic uveal melanoma.1 The update follows the January 2022 U.S. Food and Drug Administration (FDA) approval of tebentafusp-tebn for patients with previously...
ASCO Guideline Update Aims to Improve Patient Outcomes for HER2-Positive Breast Cancer With Brain Metastases
Rapid developments over the past decade in the treatment of patients with advanced HER2-positive breast cancer may lead to better outcomes and improved quality of life for patients with brain metastases, according to findings incorporated into a new ASCO guideline update.1 “The difference this...
Moffitt Mourns the Loss of Research Giant Robert J. Gillies, PhD
Moffitt Cancer Center and the global research community have lost a great leader, scientist, and collaborator. Robert J. Gillies, PhD, died on June 7 after an extended illness. He was 69 years old. His recruitment in 2008 elevated Moffitt’s scientific stature, and his vision and work over the past...
Cautious Optimism About Mining for Patient-Centric Data
“If we have data, let’s look at it. If all we have are opinions, let’s go with mine.” —James Barksdale In this issue of The ASCO Post, Daniel Vorobiof, MD, and Irad Deutsch, principles at Belong.Life, a patient-oriented website whose self-described mission is to improve patient quality of life and ...
Shaping the Future of Cancer Care: The Value of Managing Aggregated Data From Patients’ Online Communities
In 2021, more than 1.9 million people in the United States were estimated to be diagnosed with cancer, and that number continues to increase yearly. Medical research is critical in prolonging survival and improving the quantity and quality of life of patients. Cancer research is one of the most...
ASTRO Welcomes New Vice President of Education and Director of Diversity, Equity, and Inclusion
The American Society for Radiation Oncology (ASTRO) recently hired Chris Neumann as its new Vice President of Learning and Education, and Kirsta Suggs as its first Director of Diversity, Equity, and Inclusion (DEI). ASTRO is the world’s largest radiation oncology society, with nearly 10,000 members ...
Circulating Tumor DNA–Guided Approach to Treating Stage II Colon Cancer
The use of postoperative circulating tumor DNA (ctDNA) in stage II colon cancer spared many patients the need for adjuvant chemotherapy without compromising recurrence-free survival, according to the phase II DYNAMIC study.1 “The strategy of using ctDNA results to inform treatment almost halved...
ASH Statement on Diversity, Equity, and Inclusion Toolkit
The American Society of Hematology (ASH) recently announced its recognition and appreciation of Pride Month by highlighting the latest addition to the LGBTQIA+ [(lesbian, gay, bisexual, transgender, queer/questioning, intersex, asexual/agender/ally] section of ASH’s Diversity, Equity, and Inclusion ...
Cleveland Clinic Appoints Alex A. Adjei, MD, PhD, as Chair of Taussig Cancer Institute
Alex A. Adjei, MD, PhD, is the new Chair of Cleveland Clinic Taussig Cancer Institute. Previously, he served as Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Adjei also oversaw ...
Death and Clinical Trials in the Plague Years
“Everybody knows that pestilences have a way of recurring in the world; yet somehow, we find it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet always plagues and wars take people equally by surprise.” —Albert Camus, The...
Expert Point of View: Katherine Janeway, MD
Invited discussant of the rEECur trial, Katherine Janeway, MD, of Harvard Medical School, said that her comments pertained to Ewing sarcoma as well as to all rare cancers, “which comprise about 25% of all cancers diagnosed.” “Ewing sarcoma is quite rare, arising in the bone in about 75% of...
Study Finds Black and Hispanic Men With Throat Cancer Are Experiencing Higher Mortality; White Men Are Increasingly Being Diagnosed at a Late Stage
Hispanic and Black men are dying from human papillomavirus (HPV)-associated throat cancer at a higher rate than White men, and most new cases being diagnosed in non-Hispanic White men are late-stage disease, according to a new study published by Villalona et al in the Annals of Cancer ...
Does Tumor Mutational Burden Influence Response to PD-1/PD-L1 Inhibitors Among Patients With Advanced NSCLC?
In a retrospective cohort study reported in JAMA Oncology, Ricciuti et al found that patients with advanced non–small cell lung cancer (NSCLC) with higher tumor mutational burden (TMB) had better outcomes with PD-1/PD-L1 inhibitor treatment vs those with lower TMB across thresholds of PD-L1...
Phase III Trial Reports Quizartinib Doubles Overall Survival in FLT3-ITD–Positive AML
A new treatment option has doubled overall survival for a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to data presented during the Presidential Symposium at the European Hematology Association (EHA) 2022 Congress in Vienna.1 Findings from the phase III...
Inspired by the TV Show M*A*S*H, Lori Wilson, MD, FACS, Achieves Many Firsts as a Leader in Oncology
Lori Wilson, MD, FACS, Chief of Surgical Oncology, Associate Dean of Faculty Development and Diversity, and former Program Director of the General Surgical Residency at Howard University Hospital, is the first woman to hold the position of Division Chief as well as the first tenured Professor of...
Addition of Atezolizumab to Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Breast Cancer: IMpassion050
As reported in the Journal of Clinical Oncology by Jens Huober, MD, and colleagues, the phase III IMpassion050 trial showed no significant improvement in pathologic complete response rate with the addition of atezolizumab to neoadjuvant pertuzumab/trastuzumab and chemotherapy in patients with...
